Alphavirus vectors in vaccine development

Journal of Vaccines and Vaccination

Volumn 3, Issue 3, 2012, Pages

  Lundstrom, Kenneth ^a  

^a PanTherapeutics ^*  (Switzerland)

Author keywords

Alphaviruses; DNA vaccines; Neutralizing antibodies; Protection against viral; Tumor challenges; Viral vectors

Indexed keywords

EID: 84879830944     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000139     Document Type: Review

References (104)

1. Strauss JH, Strauss EG (1994) The alphaviruses: gene expression, replication and evolution. Microbial Rev 58: 491-562.
2. Kelvin AA (2011) Outbreak of Chikungunya in the Republic of Congo and the global picture. J Infect Dev Ctries 5: 441-444.
3. Mathiot CC, Grimaud G, Garry P (1990) An outbreak of Semliki Forest virus infections in Central African Republic. Am J Trop Med Hyg 42: 386-393.
4. Weaver SC, Salas R, Rico-Hesse R (1996) Remergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet 348: 436-440.
5. Liljeström P, Garoff H (1991) A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology 9: 1356-1361.
6. Xiong C, Levis R, Shen P, Schlesinger, S, Rice CM, et al. (1989) Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243: 1188-1191.
7. Davis NL, Brown KW, Johnston RE (1989) In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virol 171: 189-204.
8. Lundstrom K, Schweizer C, Rotmann D, Hermann D, Schneider EM (2001) Semliki Forest virus vectors: efficient vehicles for in vitro and in vivo gene delivery. FEBS Lett 504: 99-103.
9. Lundstrom K (2003) Semliki Forest virus vectors for rapid and high-level expression of integral membrane proteins. Biochim Biophys Acta 1610: 90-96.
10. Ehrengruber MU, Lundstrom K, Schweitzer C, Heuss C, Schlesinger S. et al. (1999) Recombinant Semliki Forest virus and Sindbis virus infect efficiently neurons in hippocampal slice cultures. Proc Natl Acad Sci USA 96: 7041-7046.
11. Lundstrom K, Richards JG, Pink JR, Jenck F (1999) Efficient in vivo expression of a reporter gene in rat brain after injection of recombinant replication-deficient Semliki Forest virus. Gene Ther Mol Biol 3: 15-23.
12. Lundstrom K (2003) Alphavirus vectors for vaccine production and gene therapy. Exp Rev Vacc 2: 447-459.
13. Malone JG, Berglund PJ, Liljestrom P, Rhodes GH, Malone RW (1997) Mucosal immune responses associated with polynucleotide vaccination. Behring Inst Mitt 98: 63-72.
14. Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL et al. (2000) Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects against lethal infection with Hong Kong-origin H5N1 viruses. Virol 278: 55-59.
15. Brand D, Lemiale F, Turbica I, Buzelay L, Brunet S et al. (1998) Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res Hum Retroviruses 14:1369-1377.
16. Giraud A, Ataman-Onal Y, Battail N, Piga N, Brand D et al. (1999) Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. J Virol Methods 79: 75-84.
17. Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R et al. (1997) Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol. 71: 3031-3038.
18. Wilson JA, Hart MK (2001) Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein. J Virol 75: 2660-2664.
19. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE et al. (1997) Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virol 239: 389-401.
20. Bosworth B, Erdman MM, Stine DL, Harris I, Irwin C et al. (2010) Replicon particle vaccine protects swine against influenza. Comp Immunol Microbiol Infect Dis. 33: e99-e103.
21. Erdman MM, Kamrud KI, Harris DL, Smith J (2010) Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept. Vaccine 28: 594-596.
22. Yang SG, Wo JE, Li MW, Mi FF, Yu CB et al. (2009) Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1). Vaccine 27: 7451-7458.
23. Sheahan T, Whitmore A, Long K, Ferris M, Rockx B et al. (2011) Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol 85: 217-230.
24. Sun Y, Li N, Li HY, Li M, Qiu HJ (2010) Enhanced immunity against classical swine fever in pigs induced by prime-boost immunization using an alphavirus replicon-vectored DNA vaccine and a recombinant adenovirus. Vet Immunol Immunopathol 137: 20-27.
25. Defang GN, Khetawat D, Broder CC, Quinnan GV Jr. (2010) Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 29: 212-220.
26. Bhardwaj N, Heise MT, Ross TM (2010) Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis 4: e725.
27. Xu R, Srivastava IK, Greer CE, Zarkikh I, Kraft Z, et al. (2006) Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses 22: 1022-1030.
28. Barnett SW, Burke B, Sun Y, Kan E, Legg H et al. (2010) Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 84: 5975-585.
29. Pasetti MF, Ramirez K, Resendiz-Albor A, Ulmer J, Barry EM et al. (2009) Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibodysecreting cells, memory B cells, and Th1-type cytokines as correlates of immunity. J Virol 83: 2789-2794.
30. Pan CH, Greer CE, Hauer D, Legg HS, Lee EY et al. (2010) A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol 84: 3798-3807.
31. Hooper JW, Ferro AM, Golden JW, Silvera P, Dudek J et al. (2009) Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28: 494-511.
32. Saxena S, Dahiya SS, Sonwane AA, Patel CL, Saini M et al. (2008) A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Vaccine 26: 6592-6601.
33. Andersson C, Vasconcelos NM, Sievertzon M, Haddad D, Liljeqvist S (2001) Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332. Scand J Immunol 54: 117-124.
34. Kirman JR, Turon T, Su H, Li A, Kraus C, et al. (2003) Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun 71: 575-579.
35. Li N, Yu YZ, Yu WY, Sun ZW (2011) Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GMCSF gene adjuvant. Immunopharmacol Immunotoxicol 33: 211-219.
36. Cabrera A, Sáez D, Céspedes S, Andrews E, Oñate A (2009) Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology 214: 467-474.
37. Thomas JM, Moen ST, Gnade BT, Vargas-Inchaustegui DA, Foltz SM, et al. (2009) Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin. Clin Vaccine Immunol 16: 1696-1699.
38. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US et al. (1999) Cancer therapy using a self-replicating RNA vaccine. Nat Med 5: 823-827.
39. Colmenero P, Liljeström P, Jondal M. (1999) Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther 6: 1728-1733.
40. Velders MP, McElhiney S, Cassetti MC, Eiben GL, Higgins T et al. (2001) Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 61: 7861-7867.
41. Riezebos-Brilman A, Regts J, Chen M, Wilschut J, Daemen T (2009) Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine 27: 701-707.
42. Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, et al. (2010) Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 5: e12670.
43. Lundstrom K. (2005) Biology and application of alphaviruses in gene therapy. Gene Ther 12: S92-S97.
44. Bernstein DI, Reap EA, Katen K, Watson A, Smith K, et al. (2009) Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28: 484-493.
45. Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, et al. (2010) An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 120: 3234-3241.
46. Carroll TD, Matzinger SR, Barro M, Fritts L, McChesney MB, et al. (2011) Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques. Vaccine 29: 931-940.
47. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS (2009) Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol 83: 3212-3227.
48. Thompson JM, Whitmore AC, Staats HF, Johnston RE (2008) Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to codelivered antigen. Vaccine 26: 4267-4275.
49. Bergen MJ, Pan CH, Greer CE, Legg HS, Polo JM, et al. (2010) Comparison of the immune responses induced by chimeric alphavirus-vectored and formalininactivated alum-precipitated measles vaccines in mice. PLoS One 5: e10297.
50. Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, et al. (2011) Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol 85: 5764-5772.
51. Walczak M, de Mare A, Riezebos-Brilman A, Regts J, Hoogeboom BN, et al. (2011) Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. Mol Pharm 8: 65-77.
52. Bennett AM, Elvin SJ, Wright AJ, Jones SM, Phillpotts RJ (2000) An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 19: 337-347.
53. Hart MK, Caswell-Stephan K, Bakken R, Tammariello R, Pratt W, et al. (2000) Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 18: 3067-3075.
54. Schoepp RJ, Smith JF, Parker MD (2002) Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates. Virology 302: 299-309.
55. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, et al. (2000) Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 62: 681-685.
56. Kim DY, Atasheva S, Foy NJ, Wang E, Frolova EI, et al. (2011) Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J Virol 85: 4363-4376.
57. Darwin JR, Kenney JL, Weaver SC (2011) Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus. Am J Trop Med Hyg 84: 1012-1015.
58. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, et al. (2011) A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 5: e928.
59. Dupuy LC, Richards MJ, Reed DS, Schmaljohn CS (2010) Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine 28: 7345-7350.
60. Prow TW, Chen X, Prow NA, Fernando GJ, Tan CS, et al. (2010) Nanopatchtargeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 6: 1776-1784.
61. Dash PK, Tiwari M, Santhosh SR, Parida M, Lakshmana Rao PV (2008) RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun 376: 718-722.
62. Kamrud KI, Coffield VM, Owens G, Goodman C, Alterson K, et al. (2010) In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs. J Virol 84: 7713-7725.
63. Reddy JR, Kwang J, Varthakavi V, Lechtenberg KF, Minocha HC (1999) Semiliki forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells. Comp Immunol Microbiol Infect Dis 22: 231-246.
64. Balasuriya UB, Heidner HW, Hedges JF, Williams JC, Davis NL, et al. (2000) Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. J Virol 74: 10623-10630.
65. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, et al. (2000) Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19: 142-153.
66. Wilson JA, Bray M, Bakken R, Hart MK (2001) Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 286: 384-390.
67. Driver DA, Latham EM, Polo JM, Belli BA, Banks TA, et al. (1995) Layered amplification of gene expression with a DNA gene delivery system. Ann N Y Acad Sci 772: 261-264.
68. Vidalin O, Fournillier A, Renard N, Chen M, Depla E, et al. (2000) Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens. Virology 276: 259-270.
69. Brinster C, Chen M, Boucreux D, Paranhos-Baccala G, Liljeström P, et al. (2002) Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 83: 369-381.
70. Hsu KF, Hung CF, Cheng WF, He L, Slater LA, et al. (2001) Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 8: 376-383.
71. Cheng WF, Hung CH, Chai CY, Hsu KF, He L, et al. (2001) Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 75: 2368-2376.
72. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, et al. (2001) Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 166: 6218-6226.
73. Schlesinger S, Dubensky TW (1999) Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol 10: 434-439.
74. Hariharan MJ, Driver DA, Townsend K, Brumm D, Polo JM, et al. (1998) DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 72: 950-958.
75. Phenix KV, Wark K, Luke CJ, Skinner MA, Smyth JA, et al. (2001) Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development. Vaccine 19: 3116-3123.
76. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljeström P (1998) Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16: 562-565.
77. Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, et al. (1994) Selfreplicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12: 1510-1514.
78. Vignuzzi M, Gerbaud S, van der Werf S, Escriou N (2001) Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein. J Gen Virol 82: 1737-1747.
79. Pugachev KV, Mason PW, Shope RE, Frey TK (1995) Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 212: 587-594.
80. Fleeton MN, Liljeström P, Sheahan BJ, Atkins GJ (2000) Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol 81: 749-758.
81. Morris-Downes MM, Phenix KV, Smyth J, Sheahan BJ, Lileqvist S, et al. (2001) Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19: 1978-1988.
82. Hevey M, Negley D, VanderZanden L, Tammariello RF, Geisbert J, et al. (2001) Marburg virus vaccines: comparing classical and new approaches. Vaccine 20: 586-593.
83. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A (1998) Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251: 28-37.
84. Colombage G, Hall R, Pavy M, Lobigs M (1998) DNA-based and alphavirusvectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250: 151-163.
85. Harrington PR, Yount B, Johnston RE, Davis N, Moe C, et al. (2002) Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol 76: 730-742.
86. Fleeton MN, Chen M, Berglund P, Rhodes G, Parker SE, et al. (2001) Selfreplicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183: 1395-1398.
87. Chen M, Hu KF, Rozell B, Orvell C, Morein B, et al. (2002) Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 169: 3208-3216.
88. Kamrud KI, Hooper JW, Elgh F, Schmaljohn CS (1999) Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters. Virology 263: 209-219.
89. Berglund P, Quesada-Rolander M, Putkonen P, Biberfeld G, Thorstensson R, et al. (1997) Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses 13: 1487-1495.
90. Tsuji M, Bergmann CC, Takita-Sonoda Y, Murata K, Rodrigues EG, et al. (1998) Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 72: 6907-6910.
91. Krasemann S, Jürgens T, Bodemer W (1999) Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. J Biotechnol 73: 119-129.
92. Lee JS, Dyas BK, Nystrom SS, Lind CM, Smith JF et al. (2002) Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. J Infect Dis 185: 1192-1196.
93. Yamanaka R, Zullo SA, Ramsey J, Yajima N, Tsuchiya N, et al. (2002) Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 97: 611-618.
94. Daemen T, Regts J, Holtrop M, Wilschut J (2002) Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther 9: 85-94.
95. Yamanaka R, Zullo SA, Tanaka R, Ramsey J, Blaese M, et al. (2000) Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg Focus 9: e7.
96. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, et al. (2002) Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13: 553-568.
97. Colmenero P, Chen M, Castaños-Velez E, Liljeström P, Jondal M (2002) Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int J Cancer 98: 554-560.
98. Ying H, Zeng G, Black KL (2001) Innovative cancer vaccine strategies based on the identification of tumour-associated antigens. BioDrugs 15: 819-831.
99. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, et al. (2003) Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9: 33-39.
100. Bennett AM, Elvin SJ, Wright AJ, Jones SM, Phillpotts RJ (2000) An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 19: 337-347.
101. Hart MK, Caswell-Stephan K, Bakken R, Tammariello R, Pratt W, et al. (2000) Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 18: 3067-3075.
102. Elvin SJ, Bennett AM, Phillpotts RJ (2002) Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J Med Virol 67: 384-393.
103. Berglund P, Sjöberg M, Garoff H, Atkins GJ, Sheahan BJ, et al. (1993) Semliki Forest virus expression system: production of conditionally infectious particles. Biotechnology (NY) 11: 916-920.
104. Smerdou C, Liljeström P (1999) Two-helper RNA system for production of recombinant Semliki Forest virus particles. J Virol 73: 1092-1098.